High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases.
- Author:
Jian-Fei ZHU
1
,
2
;
Ling CAI
;
Xue-Wen ZHANG
;
Yin-Sheng WEN
;
Xiao-Dong SU
;
Tie-Hua RONG
;
Lan-Jun ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; metabolism; Brain Neoplasms; blood; metabolism; secondary; Carcinoma, Non-Small-Cell Lung; blood; metabolism; pathology; Female; Fibrinogen; metabolism; Follow-Up Studies; Humans; Lung Neoplasms; blood; metabolism; pathology; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Partial Thromboplastin Time; Platelet Count; Smoking; Survival Rate; Young Adult
- From:Chinese Journal of Cancer 2014;33(2):96-104
- CountryChina
- Language:English
- Abstract: High expression of fibrinogen and platelets are often observed in non-small cell lung cancer (NSCLC) patients with local regional or distant metastasis. However, the role of these factors remains unclear. The aims of this study were to evaluate the prognostic significance of plasma fibrinogen concentration and platelet count, as well as to determine the overall survival of NSCLC patients with brain metastases. A total of 275 NSCLC patients with brain metastasis were enrolled into this study. Univariate analysis showed that high plasma fibrinogen concentration was associated with age≥65 years (P = 0.011), smoking status (P = 0.009), intracranial symptoms (P = 0.022), clinical T category (P = 0.010), clinical N category (P = 0.003), increased partial thromboplastin time (P < 0.001), and platelet count (P < 0.001). Patients with low plasma fibrinogen concentration demonstrated longer overall survival compared with those with high plasma fibrinogen concentration (median, 17.3 months versus 11.1 months; P≤0.001). A similar result was observed for platelet counts (median, 16.3 months versus 11.4 months; P = 0.004). Multivariate analysis showed that both plasma fibrinogen concentration and platelet count were independent prognostic factors for NSCLC with brain metastases (R2 = 1.698, P < 0.001 and R2 = 1.699, P < 0.001, respectively). Our results suggest that high plasma fibrinogen concentration and platelet count indicate poor prognosis for NSCLC patients with brain metastases. Thus, these two biomarkers might be independent prognostic predictors for this subgroup of NSCLC patients.
